Century Therapeutics presents CNTY-813 preclinical data showing durable glucose control

Century Therapeutics announced new preclinical data for CNTY-813, an iPSC-derived islet replacement therapy that demonstrated durable glucose control for over eight months and immune evasion without immunosuppression in preclinical models. The company plans to submit an IND application in 4Q 2026 with initial clinical data expected in 2H 2027, positioning the therapy as a potential functional cure for Type 1 Diabetes.